Scribeberryは、臨床医向けに設計された高度なAI搭載医療スクライブです。患者との対話をリスニングし、構造化されたメモを生成し、EMRとシームレスに統合することで、臨床文書作成を自動化します。これにより、医療提供者は毎日数時間を節約し、燃え尽き症候群を軽減し、患者ケアにより集中できます。
ScribeMDは、医療専門家向けに設計されたHIPAA準拠のAI医療書記です。患者との対話を聞き取り、文字起こしし、構造化された文書を生成することで、臨床ノートの作成を自動化します。これにより、医師は管理業務を削減し、患者一人当たりの時間を大幅に節約し、より患者ケアに集中できます。
製品概要
Scribeberry 製品概要
Scribeberryは、臨床医向けに設計された高度なAI搭載医療スクライブです。患者との対話をリスニングし、構造化されたメモを生成し、EMRとシームレスに統合することで、臨床文書作成を自動化します。これにより、医療提供者は毎日数時間を節約し、燃え尽き症候群を軽減し、患者ケアにより集中できます。
ScribeMD 製品概要
ScribeMDは、医療専門家向けに設計されたHIPAA準拠のAI医療書記です。患者との対話を聞き取り、文字起こしし、構造化された文書を生成することで、臨床ノートの作成を自動化します。これにより、医師は管理業務を削減し、患者一人当たりの時間を大幅に節約し、より患者ケアに集中できます。
Detailed feature comparison
| Feature | Scribeberry | ScribeMD |
|---|---|---|
| 主要カテゴリー | バーチャル書記 | 医療文書 |
| 追加日 | 2025-08-03 | 2025-08-10 |
| 価格 | フリーミアム | 有料 |
| 公式サイト | scribeberry.com | www.scribemd.ai |
| 製品タイプ | ウェブサイト | ウェブサイト |
| Performance data | ||
| ユーザー評価 | 未確認 | 未確認 |
| コメント | 0 | 0 |
| 月間訪問数 | 67.5K | 4.5K |
| 月間成長率 | 1.2% | 21.4% |
| お気に入り | 113 | 104 |
| Details | 詳細を見る | 詳細を見る |
Scribeberry vs ScribeMD monthly traffic
Compare Scribeberry and ScribeMD by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
How to interpret the traffic data
In the Scribeberry vs ScribeMD monthly traffic comparison, Scribeberry currently shows 67.5K visits and ScribeMD shows 4.5K; Scribeberry has about 14.9 times the visible traffic of ScribeMD, an absolute difference of about 63K visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
Scribeberry monthly traffic:
Latest traffic
Monthly traffic trend
- 2025/9: 61.4K 月間訪問数
- 2026/1: 60.8K 月間訪問数
- 2026/2: 66.9K 月間訪問数
- 2026/3: 65K 月間訪問数
- 2026/4: 66.7K 月間訪問数
- 2026/5: 67.5K 月間訪問数
主要地域
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇨🇦Canada | 93.87% | 63.4K |
| 🇺🇸United States | 5.25% | 3.5K |
| 🇮🇳India | 0.78% | 527 |
| 🇷🇺Russia | 0.1% | 68 |
流入元
| Source type | Percentage | Traffic |
|---|---|---|
| ダイレクト | 70.25% | 47.4K |
| 参照元 | 29.75% | 20.1K |
検索キーワード
ScribeMD monthly traffic:
Latest traffic
Monthly traffic trend
- 2025/9: 4.9K 月間訪問数
- 2026/1: 6K 月間訪問数
- 2026/2: 4.2K 月間訪問数
- 2026/3: 2K 月間訪問数
- 2026/4: 3.7K 月間訪問数
- 2026/5: 4.5K 月間訪問数
主要地域
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 84.66% | 3.8K |
| 🇪🇸Spain | 14.21% | 644 |
| 🇮🇳India | 1.13% | 51 |
検索キーワード
Usage comparison
Compare the core capabilities of Scribeberry and ScribeMD
Scribeberry Core features
ScribeMD Core features
Use cases
Scribeberry Use cases
ScribeMD Use cases
Scribeberry vs ScribeMD:In-depth comparison and selection guidance
First decide whether the products solve the same kind of need
This in-depth Scribeberry vs ScribeMD comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. Scribeberry is primarily listed under “バーチャル書記”, while ScribeMD is primarily listed under “医療文書”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (Scribeberry: バーチャル書記; ScribeMD: 医療文書); Pricing (Scribeberry: Freemium; ScribeMD: Paid); Monthly visits (Scribeberry: 67.5K; ScribeMD: 4.5K); Monthly growth (Scribeberry: 1.2%; ScribeMD: 21.4%); Favorites (Scribeberry: 113; ScribeMD: 104). These facts are more useful for selection than brand visibility alone.
What market visibility and monthly traffic mean
In the Scribeberry vs ScribeMD monthly traffic comparison, Scribeberry currently shows 67.5K visits and ScribeMD shows 4.5K; Scribeberry has about 14.9 times the visible traffic of ScribeMD, an absolute difference of about 63K visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
If public market visibility is an important first-pass criterion, investigate Scribeberry first. The final choice should still follow taxonomy, use case, and a real trial because higher traffic does not prove broader capabilities or better workflow fit.
Product positioning, use cases, and roles
Scribeberry and ScribeMD currently overlap in shared categories: 医療文書、文字起こし; shared tags: 臨床文書、医師生産性、医療AI、HIPAA準拠、医療クラーク. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
Scribeberry's unique categories/tags are バーチャル書記、バーンアウト予防、EMR連携、医療記録、文字起こし; ScribeMD's are 自動化、EMR自動化、医療転写、患者記録、音声テキスト変換. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
What ratings, comments, and favorites can tell you
Scribeberry has no verified rating, 0 comments, 113 favorites, and 106 likes;ScribeMD has no verified rating, 0 comments, 104 favorites, and 124 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Selection guidance by actual need
When to evaluate Scribeberry first
Put Scribeberry on the priority trial list when the task aligns with “バーチャル書記” and especially バーチャル書記、バーンアウト予防、EMR連携、医療記録、文字起こし. This follows recorded positioning and does not imply unlisted capabilities are absent.
Scribeberry also currently records: pricing is freemium, product type is website, 67.5K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
When to evaluate ScribeMD first
Put ScribeMD on the priority trial list when the task aligns with “医療文書” and especially 自動化、EMR自動化、医療転写、患者記録、音声テキスト変換. This follows recorded positioning and does not imply unlisted capabilities are absent.
ScribeMD also currently records: pricing is paid, product type is website, 4.5K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
How to validate the recommendation before deciding
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in Scribeberry and ScribeMD, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.




